Literature DB >> 17214598

Sulodexide: a renewed interest in this glycosaminoglycan.

D Adam Lauver1, Benedict R Lucchesi.   

Abstract

Glycosaminoglycans (GAGs) are the most abundant group of heteropolysaccharides found in the body. These long unbranched molecules contain a repeating disaccharide unit. GAGs are located primarily in the extracellular matrix or on the surface of cells. These molecules serve as lubricants in the joints while at the same time providing structural rigidity to cells. Sulodexide is a highly purified glycosaminoglycan composed of a fast mobility heparin fraction as well as dermatan sulfate. Sulodexide differs from other glycosaminoglycans, like heparin, by having a longer half-life and a reduced effect on systemic clotting and bleeding. In addition, sulodexide demonstrates a lipolytic activity that is increased in comparison to heparin. Oral administration of sulodexide results in the release of tissue plasminogen activator and an increase in fibrinolytic activities. An increasing body of research has demonstrated the safety and efficacy of sulodexide in a wide range of vascular pathologies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17214598     DOI: 10.1111/j.1527-3466.2006.00214.x

Source DB:  PubMed          Journal:  Cardiovasc Drug Rev        ISSN: 0897-5957


  23 in total

1.  Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy.

Authors:  David K Packham; Rory Wolfe; Anne T Reutens; Tomas Berl; Hiddo Lambers Heerspink; Richard Rohde; Sara Ivory; Julia Lewis; Itamar Raz; Thomas B Wiegmann; Juliana C N Chan; Dick de Zeeuw; Edmund J Lewis; Robert C Atkins
Journal:  J Am Soc Nephrol       Date:  2011-10-27       Impact factor: 10.121

2.  Treatment of central and sensorineural tinnitus with orally administered Melatonin and Sulodexide: personal experience from a randomized controlled study.

Authors:  G Neri; A De Stefano; C Baffa; G Kulamarva; P Di Giovanni; G Petrucci; A Poliandri; F Dispenza; L Citraro; A Croce
Journal:  Acta Otorhinolaryngol Ital       Date:  2009-04       Impact factor: 2.124

3.  Matrix metalloproteinase activity and glycosaminoglycans in chronic venous disease: the linkage among cell biology, pathology and translational research.

Authors:  Ferdinando Mannello; Joseph D Raffetto
Journal:  Am J Transl Res       Date:  2010-11-23       Impact factor: 4.060

4.  Sulodexide promotes arterial relaxation via endothelium-dependent nitric oxide-mediated pathway.

Authors:  Joseph D Raffetto; Fiorella Calanni; Paolo Mattana; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2019-04-20       Impact factor: 5.858

Review 5.  The role of sulodexide in the treatment of diabetic nephropathy.

Authors:  Ram Weiss; Robert Niecestro; Itamar Raz
Journal:  Drugs       Date:  2007       Impact factor: 9.546

6.  Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathy.

Authors:  Michele Rossini; Takashi Naito; Haichun Yang; Michael Freeman; Ellen Donnert; Li-Jun Ma; Stephen R Dunn; Kumar Sharma; Agnes B Fogo
Journal:  Nephrol Dial Transplant       Date:  2010-01-07       Impact factor: 5.992

7.  Use of sulodexide in patients with peripheral vascular disease.

Authors:  J Lasierra-Cirujeda; P Coronel; Mj Aza; M Gimeno
Journal:  J Blood Med       Date:  2010-06-15

8.  Mechanisms of Lower Extremity Vein Dysfunction in Chronic Venous Disease and Implications in Management of Varicose Veins.

Authors:  Joseph D Raffetto; Raouf A Khalil
Journal:  Vessel Plus       Date:  2021-05-29

9.  A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal transition.

Authors:  Valentina Masola; Maurizio Onisto; Gianluigi Zaza; Antonio Lupo; Giovanni Gambaro
Journal:  J Transl Med       Date:  2012-10-24       Impact factor: 5.531

10.  Sulodexide decreases albuminuria and regulates matrix protein accumulation in C57BL/6 mice with streptozotocin-induced type I diabetic nephropathy.

Authors:  Susan Yung; Mel K M Chau; Qing Zhang; Chen Zhu Zhang; Tak Mao Chan
Journal:  PLoS One       Date:  2013-01-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.